Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
CUEthis companyCue Biopharma, Inc.	$19.03	-1.09×	1.09×	1.05×	-0.24×	-850.1%	100.0%	-96.6%	-96.9%	-100.6%	-86.6%	-75.6%	0.16×	0.93×	-74.29×	2.74×	0.0%	2	-30.14	1	D+
EQEquillium, Inc.	$1.59	-3.97×	4.98×	0×	-5.06×	-77.1%	0.0%	0.0%	0.0%	-78.3%	-83.3%	-16.0%	0.03×	1.33×	0×	10.32×	0.0%	1	14.51	2	C
IPSCCentury Therapeutics, Inc.	$1.81	-9.04×	0.54×	0.79×	19.64×	85.0%	88.0%	-13.8%	-8.8%	-6.0%	-7.2%	-121.6%	0.27×	-5.3×	0×	5.97×	0.0%	1	-1.94	2	C
NRXPNRx Pharmaceuticals, Inc.	$2.42	-2.02×	-3.64×	47.35×	-1.83×	-67.8%	58.8%	-1324.4%	-2336.5%	179.6%	106.0%	-24.3%	-0.04×	0.26×	-24.18×	0.31×	0.0%	4	-13.9	2	C+
OTLKOutlook Therapeutics, Inc.	$0.45	-0.59×	-0.84×	19.1×	-0.77×	82.8%	46.5%	-4744.3%	-4416.2%	193.9%	-2357.6%	-191.9%	-0.94×	-0.35×	-236.86×	0.38×	0.0%	3	-41.23	2	C
SNTISenti Biosciences, Inc.	$0.16	-0.38×	41.84×	10,628.51×	-4.26×	-132.5%	-16431.8%	-289668.2%	-279263.6%	-1099.3%	-149.7%	-18.7%	5.17×	-0.22×	0×	1.67×	0.0%	2	-20.88	2	C
Peer median	—	-2.02×	0.54×	19.1×	-1.83×	-67.8%	46.5%	-1324.4%	-2336.5%	-6.0%	-83.3%	-24.3%	0.03×	-0.22×	0×	1.67×	0.0%	2	-13.9	2	—